Application of ATRX in diagnosis and prognostic evaluation of glioma
10.3760/cma.j.issn.0529-5807.2017.10.006
- VernacularTitle: ATRX在胶质瘤诊断及患者预后评估中的应用
- Author:
Zhuo LI
1
;
Yueshan PIAO
;
Liyan ZHANG
;
Leiming WANG
;
Dandan WANG
;
Yongjuan FU
;
Yanning CAI
;
Dehong LU
Author Information
1. Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
- Publication Type:Journal Article
- Keywords:
Glioma;
Tumor suppressor protein p53;
Prognosis;
X-linked alpha thalassemia mental retardation syndrome gene
- From:
Chinese Journal of Pathology
2017;46(10):690-694
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the diagnostic and prognostic implications of ATRX mutation and p53 mutation in patients with glioma.
Methods:The clinicopathologic and molecular features of Chinese adult glioma patients, including diffuse and anaplastic astroastrocytoma with IDH mutation, oligodendroglioma and anaplastic oligodendroglioma with IDH mutation and 1p/19q co-deletion and diffuse astroastrocytoma with IDH wild type were reviewed and tested for ATRX loss expression and p53 overexpression.
Results:Loss of ATRX expression was seen in 85.19% (23/27) diffuse and anaplastic astroastrocytoma with IDH mutation, higher than that of oligodendroglial tumors (0/53; P<0.01). Loss of ATRX expression was strongly linked to p53 overexpression(69.57%, 16/23). The patients who lost ATRX expression combined with normal p53 expression survived longer(P=0.013).
Conclusions:ATRX mutation is a molecular marker for astrocytic tumors. ATRX mutation combined with p53 mutation can predict prognosis of patients with glioma.
